News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
693,547 Results
Type
Article (51508)
Company Profile (217)
Press Release (641822)
Multimedia
Podcasts (97)
Webinars (15)
Section
Business (191202)
Career Advice (2981)
Deals (34877)
Drug Delivery (110)
Drug Development (78895)
Employer Resources (172)
FDA (16728)
Job Trends (15375)
News (329936)
Policy (32228)
Tag
Academia (2900)
Academic (1)
Accelerated approval (10)
Adcomms (28)
Allergies (103)
Alliances (51620)
ALS (118)
Alzheimer's disease (1523)
Antibody-drug conjugate (ADC) (171)
Approvals (16709)
Artificial intelligence (353)
Autoimmune disease (35)
Automation (18)
Bankruptcy (324)
Best Places to Work (12355)
BIOSECURE Act (19)
Biosimilars (123)
Biotechnology (154)
Bladder cancer (98)
Brain cancer (35)
Breast cancer (376)
Cancer (2958)
Cardiovascular disease (225)
Career advice (2497)
Career pathing (33)
CAR-T (201)
CDC (34)
Cell therapy (541)
Cervical cancer (24)
Clinical research (64747)
Collaboration (1089)
Company closure (2)
Compensation (686)
Complete response letters (25)
COVID-19 (2771)
CRISPR (67)
C-suite (335)
Cystic fibrosis (118)
Data (3020)
Decentralized trials (2)
Denatured (30)
Depression (63)
Diabetes (358)
Diagnostics (6861)
Digital health (24)
Diversity (9)
Diversity, equity & inclusion (42)
Drug discovery (147)
Drug pricing (132)
Drug shortages (27)
Duchenne muscular dystrophy (125)
Earnings (73553)
Editorial (45)
Employer branding (21)
Employer resources (153)
Events (109581)
Executive appointments (898)
FDA (18409)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (10)
Funding (974)
Gene editing (147)
Generative AI (31)
Gene therapy (410)
GLP-1 (815)
Government (4662)
Grass and pollen (6)
Guidances (178)
Healthcare (20414)
Huntington's disease (30)
IgA nephropathy (43)
Immunology and inflammation (167)
Immuno-oncology (9)
Indications (40)
Infectious disease (2953)
Inflammatory bowel disease (158)
Inflation Reduction Act (12)
Influenza (67)
Intellectual property (122)
Interviews (569)
IPO (16757)
IRA (43)
Job creations (3442)
Job search strategy (2074)
Kidney cancer (15)
Labor market (43)
Layoffs (502)
Leadership (25)
Legal (7464)
Liver cancer (77)
Lung cancer (413)
Lymphoma (206)
Machine learning (11)
Management (63)
Manufacturing (398)
MASH (94)
Medical device (14499)
Medtech (14504)
Mergers & acquisitions (18910)
Metabolic disorders (870)
Multiple sclerosis (103)
NASH (21)
Neurodegenerative disease (130)
Neuropsychiatric disorders (34)
Neuroscience (2233)
NextGen: Class of 2025 (7166)
Non-profit (4979)
Now hiring (43)
Obesity (431)
Opinion (267)
Ovarian cancer (102)
Pain (116)
Pancreatic cancer (122)
Parkinson's disease (197)
Partnered (24)
Patents (306)
Patient recruitment (163)
Peanut (54)
People (56049)
Pharmaceutical (48)
Pharmacy benefit managers (22)
Phase I (20316)
Phase II (28594)
Phase III (21305)
Pipeline (1644)
Policy (206)
Postmarket research (2366)
Preclinical (8601)
Press Release (70)
Prostate cancer (142)
Psychedelics (38)
Radiopharmaceuticals (274)
Rare diseases (503)
Real estate (5765)
Recruiting (70)
Regulatory (22707)
Reports (33)
Research institute (2598)
Resumes & cover letters (478)
Rett syndrome (9)
RNA editing (9)
RSV (53)
Schizophrenia (91)
Series A (168)
Series B (114)
Service/supplier (11)
Sickle cell disease (67)
Special edition (15)
Spinal muscular atrophy (156)
Sponsored (35)
Startups (3650)
State (2)
Stomach cancer (13)
Supply chain (76)
Tariffs (57)
The Weekly (65)
Vaccines (844)
Venture capital (52)
Weight loss (265)
Women's health (40)
Worklife (19)
Date
Today (97)
Last 7 days (317)
Last 30 days (2069)
Last 365 days (32827)
2025 (17418)
2024 (36895)
2023 (42134)
2022 (53454)
2021 (58154)
2020 (56905)
2019 (50195)
2018 (38025)
2017 (33963)
2016 (32790)
2015 (38280)
2014 (28888)
2013 (23849)
2012 (25699)
2011 (26390)
2010 (24049)
Location
Africa (901)
Alabama (69)
Alaska (7)
Arizona (201)
Arkansas (14)
Asia (41009)
Australia (7288)
California (7558)
Canada (2377)
China (697)
Colorado (331)
Connecticut (337)
Delaware (198)
Europe (94895)
Florida (1146)
Georgia (261)
Hawaii (1)
Idaho (61)
Illinois (680)
India (28)
Indiana (370)
Iowa (16)
Japan (230)
Kansas (109)
Kentucky (33)
Louisiana (16)
Maine (73)
Maryland (1073)
Massachusetts (5778)
Michigan (269)
Minnesota (472)
Mississippi (3)
Missouri (98)
Montana (32)
Nebraska (26)
Nevada (81)
New Hampshire (72)
New Jersey (2139)
New Mexico (30)
New York (2135)
North Carolina (1152)
North Dakota (10)
Northern California (3311)
Ohio (245)
Oklahoma (17)
Oregon (37)
Pennsylvania (1636)
Puerto Rico (17)
Rhode Island (37)
South America (1244)
South Carolina (36)
South Dakota (1)
Southern California (2837)
Tennessee (127)
Texas (1138)
United States (28441)
Utah (228)
Virginia (191)
Washington D.C. (72)
Washington State (657)
West Virginia (4)
Wisconsin (77)
693,547 Results for "gyros protein technologies gyros ab merged with protein technologies".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Gyros Protein Technologies Introduces Gyrolab Generic Anti-AAV Kit to Support Gene Therapy Development
Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and leading provider of peptide synthesizers today announced the introduction of its Gyrolab® Generic Anti-Adeno Associated Virus (AAV) Kit.
June 17, 2024
·
2 min read
Drug Development
Gyros Protein Technologies Introduces Gyrolab Generic Rodent ADA Kit Reagents to Support Preclinical Immunogenicity Assessment
Gyros Protein Technologies AB announced the introduction of Gyrolab® Generic Rodent Anti-Drug Antibody Kit Reagents for the detection of circulating immune complexes of human IgG with rodent anti-human IgG.
May 2, 2024
·
2 min read
Press Releases
Gyros Protein Technologies Introduces Gyrolab HEK293 HCP Type SN and Type CL Kit Reagents to Support Biotherapeutic Development
February 5, 2025
·
2 min read
Gyros Protein Technologies and Biotage partner to advance peptide purification efficiency with new automated solution
Gyros Protein Technologies AB and Biotage announced a partnership to offer Biotage® PeptiPEC, based on Gyros’ PurePep® EasyClean catch and release technology, on Biotage® Extrahera™ automated sample preparation system.
December 7, 2023
·
2 min read
Collaboration
Sanofi, Gilead Deepen Protein Degrader Pipelines in Separate Deals With Kymera
Gilead is betting up to $750 million on Kymera’s anti-CDK2 molecular glue for solid tumors, while Sanofi elected to move forward with another protein degrader from the biotech, designed to target immune-mediated diseases.
June 25, 2025
·
2 min read
·
Tristan Manalac
Gyros Protein Technologies Introduces PurePep EasyClean Auto Kit for Automated Parallel Peptide Purification
Gyros Protein Technologies AB announced the launch of its PurePep® EasyClean Auto Kit for the automated parallel purification of peptides, accelerating downstream processes for research, development, and production of simple to complex peptide drugs and therapies.
July 27, 2023
·
2 min read
Press Releases
BPGbio Presents Advances in Spatial Omics Technology and Targeted Protein Degradation Insights at ASMS 2025
May 28, 2025
·
4 min read
Funding
SpliceBio Nabs $135 Million Series B To Advance Protein Splicing Medicines
The company’s intein-based technology is initially aimed at Stargardt disease, a type of macular degeneration.
June 11, 2025
·
2 min read
·
Dan Samorodnitsky
Gyros Protein Technologies Introduces Gyrolab Generic Cyno ADA Kit Reagents to Support Pre-Clinical Immunogenicity Assessment
Gyros Protein Technologies AB, a leading provider of peptide synthesizers and reagents and a pioneer in automated nanoliter-scale immunoassays, today announced the introduction of Gyrolab® Generic Cyno Anti-Drug Antibodies (ADA) Kit Reagents, for the detection of circulating immune complexes of human IgG with cyno anti-human IgG.
May 2, 2023
·
2 min read
Gyros Protein Technologies Adds Gyrolab® Biomarker Kits to Expand Range of Ready-to-Use Kits and Reagents
Gyros Protein Technologies AB, a leading provider of peptide synthesizers and reagents and a pioneer in automated nanoliter-scale immunoassays, introduced Gyrolab® Human Cytokine Kit Reagents, the first in a range of new biomarker kits.
November 29, 2022
·
2 min read
1 of 69,355
Next
